Impact of patient characteristics on the clinical efficacy of mongersen (GED‐0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease

BACKGROUND: In a phase 2 study, mongersen, an oral antisense oligonucleotide targeting Smad7, was effective in inducing clinical remission in approximately 60% of patients with active Crohn's disease (CD). AIM: In a post hoc analysis to evaluate those patient disease characteristics that may ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Monteleone, G., Di Sabatino, A., Ardizzone, S., Pallone, F., Usiskin, K., Zhan, X., Rossiter, G., Neurath, M. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Mongersen for Crohn's Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849204/
https://www.ncbi.nlm.nih.gov/pubmed/26766141
http://dx.doi.org/10.1111/apt.13526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849204/
https://www.ncbi.nlm.nih.gov/pubmed/26766141
http://dx.doi.org/10.1111/apt.13526

Ejemplares similares